Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s … – GlobeNewswire (press release)
|
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s …
GlobeNewswire (press release) Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the results from the first clinical study of ilixadencel in patients with … |
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
Drug Discovery & Development |
Developing a Gene Therapy with Transformative Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa
Drug Discovery & Development The term “butterfly children” sounds pleasant but refers to a harsh reality: children with epidermolysis bullosa, or EB, an inherited, genetic blistering skin disorder, are born with skin as fragile as a butterfly’s wings. EB affects all races … |
|
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s …
Nasdaq Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the results from the first clinical study of ilixadencel in patients with … |